A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)

Based on synergistic anti-tumor effects between blockades of NEDD8 activating enzyme and a platinum in preclinical studies, this Phase I study is designed to investigate the safety and tolerability of pevonedistat in combination with capecitabine plus oxaliplatin as third-line or later treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Hirokazu, Takahari, Daisuke, Hara, Hiroki, Nagashima, Kengo, Adachi, Jun, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256327/
https://www.ncbi.nlm.nih.gov/pubmed/34258028
http://dx.doi.org/10.2144/fsoa-2021-0023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256327/
https://www.ncbi.nlm.nih.gov/pubmed/34258028
http://dx.doi.org/10.2144/fsoa-2021-0023

Ejemplares similares